- Home
- ASMB vs MUE Comparison
ASMB vs MUE Comparison
Compare ASMB & MUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASMB
- MUE
- Stock Information
- Founded
- ASMB 2005
- MUE 1999
- Country
- ASMB United States
- MUE United States
- Employees
- ASMB N/A
- MUE N/A
- Industry
- ASMB Biotechnology: Pharmaceutical Preparations
- MUE Investment Bankers/Brokers/Service
- Sector
- ASMB Health Care
- MUE Finance
- Exchange
- ASMB Nasdaq
- MUE Nasdaq
- Market Cap
- ASMB 198.6M
- MUE 206.2M
- IPO Year
- ASMB 2010
- MUE N/A
- Fundamental
- Price
- ASMB $21.85
- MUE $10.01
- Analyst Decision
- ASMB Strong Buy
- MUE
- Analyst Count
- ASMB 4
- MUE 0
- Target Price
- ASMB $41.33
- MUE N/A
- AVG Volume (30 Days)
- ASMB 148.4K
- MUE 62.6K
- Earning Date
- ASMB 11-06-2025
- MUE 01-01-0001
- Dividend Yield
- ASMB N/A
- MUE 4.09%
- EPS Growth
- ASMB N/A
- MUE N/A
- EPS
- ASMB N/A
- MUE N/A
- Revenue
- ASMB $33,247,000.00
- MUE N/A
- Revenue This Year
- ASMB $12.44
- MUE N/A
- Revenue Next Year
- ASMB N/A
- MUE N/A
- P/E Ratio
- ASMB N/A
- MUE N/A
- Revenue Growth
- ASMB 54.77
- MUE N/A
- 52 Week Low
- ASMB $7.75
- MUE $8.53
- 52 Week High
- ASMB $27.17
- MUE $10.17
- Technical
- Relative Strength Index (RSI)
- ASMB 40.57
- MUE 76.59
- Support Level
- ASMB $22.36
- MUE $9.37
- Resistance Level
- ASMB $23.61
- MUE $10.08
- Average True Range (ATR)
- ASMB 1.30
- MUE 0.08
- MACD
- ASMB -0.60
- MUE 0.06
- Stochastic Oscillator
- ASMB 3.37
- MUE 88.97
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
About MUE Blackrock MuniHoldings Quality Fund II Inc.
BlackRock MuniHoldings Quality Fund II Inc is a diversified, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income and capital appreciation. The fund seeks to achieve its investment objective by investing in long-term, investment-grade municipal obligations exempt from U.S. federal income taxes.